Acumen Pharmaceuticals (ABOS) Cash from Financing Activities (2021 - 2026)

Acumen Pharmaceuticals' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $35.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 99383.33% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $35.7 million (up 16725.12% YoY), while the FY2025 annual figure was -$34000.0, down 100.49% from the prior year.
• Cash from Financing Activities came in at $35.7 million for Q1 2026 at Acumen Pharmaceuticals, up from $2000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $122.8 million in Q3 2023 to a low of -$263000.0 in Q3 2022.
• A 5-year average of $16.5 million and a median of -$3500.0 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 100.51% in 2025 and jumped 99383.33% in 2026, its largest moves.
• Acumen Pharmaceuticals' Cash from Financing Activities stood at $4.2 million in 2022, then surged by 596.32% to $29.1 million in 2023, then tumbled by 100.03% to -$9000.0 in 2024, then surged by 122.22% to $2000.0 in 2025, then jumped by 1787000.0% to $35.7 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $35.7 million, $2000.0, and -$36000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.

Peer Comparison